Reduced intensity conditioning in allogeneic stem cell transplantation for AML with Down syndrome

Pediatric Blood and Cancer

Volumn 61, Issue 5, 2014, Pages 925-927

  Muramatsu, Hideki ^a   Sakaguchi, Hirotoshi ^a,b   Taga, Takashi ^c   Tabuchi, Ken ^d   Adachi, Souichi ^e   Inoue, Masami ^f   Kitoh, Toshiyuki ^g   Suminoe, Aiko ^h   Yabe, Hiromasa ⁱ   Azuma, Eichi ^j   Shioda, Yoko ^k   Ogawa, Atsushi ^l   Kinoshita, Akitoshi ^m   Kigasawa, Hisato ^d   Osugi, Yuko ⁿ   Koike, Kazutoshi ^o   Kawa, Keisei ^f   Kato, Koji ^b   Atsuta, Yoshiko ^a   Kudo, Kazuko ^p  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b JAPANESE RED CROSS NAGOYA FIRST HOSPITAL   (Japan)

^c SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^d Kanagawa Children's Center   (Japan)

^e KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^f RESEARCH INSTITUTE FOR MATERNAL AND CHILD HEALTH   (Japan)

^g Medical Center for Children Shiga   (Japan)

^h KYUSHU UNIVERSITY   (Japan)

ⁱ TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^j MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^k NATIONAL CENTER FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

^l NIIGATA CANCER CENTER HOSPITAL   (Japan)

^m ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁿ OSAKA CITY GENERAL HOSPITAL   (Japan)

^o Ibaraki Children's Hospital   (Japan)

^p SHIZUOKA CHILDREN'S HOSPITAL   (Japan)

more..

Author keywords

Acute myeloid leukemia; Allogeneic stem cell transplantation; Down syndrome; Reduced intensity conditioning

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; ETOPOSIDE; FLUDARABINE; HLA B ANTIGEN; HLA DR ANTIGEN; MELPHALAN; METHOTREXATE; TACROLIMUS; THIOTEPA;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CHILD; CLINICAL ARTICLE; DOWN SYNDROME; EVENT FREE SURVIVAL; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN CELL; HUMAN TISSUE; INFANT; MALE; MORTALITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRESCHOOL CHILD; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; RETROSPECTIVE STUDY; SCHOOL CHILD; WHOLE BODY RADIATION;

ACUTE MYELOID LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; DOWN SYNDROME; REDUCED INTENSITY CONDITIONING;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; DOWN SYNDROME; FEMALE; FOLLOW-UP STUDIES; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; INFANT, NEWBORN; LEUKEMIA, MYELOID, ACUTE; MALE; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SURVIVAL RATE; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 84895745117     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24883     Document Type: Article

References (10)

1. Fong CT, Brodeur GM. Down's syndrome and leukemia: Epidemiology, genetics, cytogenetics and mechanisms of leukemogenesis. Cancer Genet Cytogenet 1987; 28:55-76.
2. Zipursky A, Peeters M, Poon A. Megakaryoblastic leukemia and Down's syndrome: A review. Pediatr Hematol Oncol 1987; 4:211-230.
3. Gamis AS, Woods WG, Alonzo TA, et al. Increased age at diagnosis has a significantly negative effect on outcome in children with Down syndrome and acute myeloid leukemia: A report from the Children's Cancer Group Study. J Clin Oncol 2003; 21:3415-3422.
4. Abildgaard L, Ellebaek E, Gustafsson G, et al. Optimal treatment intensity in children with Down syndrome and myeloid leukaemia: Data from 56 children treated on NOPHO-AML protocols and a review of the literature. Ann Hematol 2006; 85:275-280.
5. Kojima S, Kato K, Matsuyama T, et al. Favorable treatment outcome in children with acute myeloid leukemia and Down syndrome. Blood 1993; 81:3164.
6. Kojima S, Sako M, Kato K, et al. An effective chemotherapeutic regimen for acute myeloid leukemia and myelodysplastic syndrome in children with Down's syndrome. Leukemia 2000; 14:786-7791.
7. Kudo K, Kojima S, Tabuchi K, et al. Prospective study of a pirarubicin, intermediate-dose cytarabine, and etoposide regimen in children with Down syndrome and acute myeloid leukemia: The Japanese Childhood AML Cooperative Study Group. J Clin Oncol 2007; 25:5442-5447.
8. Rubin CM, Mick R, Johnson FL. Bone marrow transplantation for the treatment of haematological disorders in Down's syndrome: Toxicity and outcome. Bone Marrow Transplant 1996; 18:533-540.
9. Meissner B, Borkhardt A, Dilloo D, et al. Relapse, not regimen-related toxicity, was the major cause of treatment failure in 11 children with Down syndrome undergoing haematopoietic stem cell transplantation for acute leukaemia. Bone Marrow Transplant 2007; 40:945-949.
10. Hitzler JK, He W, Doyle J, et al. Outcome of transplantation for acute myelogenous leukemia in children with down syndrome. Biol Blood Marrow Transplant 2013; 19:893-897.